Skip to main content

Advertisement

Table 1 Clinical features of patients with active SLE and patients with inactive SLE*

From: Functional activation of proline-rich tyrosine kinase2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus

Characteristic Patients with active disease Patients with inactive disease
  (n = 36) (n = 12)
No. of men/no. of women 5/31 2/10
Age, mean ± SD (range) years 35 ± 14 (11--69) 36 ± 12 (16--59)
Disease duration, mean ± SD (range) months 65 ± 101 (1--260) 118 ± 98 (5--216)
Disease activity   
   SLEDAI score (0--105), mean ± SD 16 ± 4 7 ± 4
   Anti-dsDNA titer, mean ± SD IU/ml 597 ± 784 49 ± 56
   CH50 level, mean ± SD units/ml 14 ± 11 26 ± 8
Clinical manifestation   
   WHO class IV nephritis 24 5
   Other than WHO class IV nephritis 12 7
   CNS disease 6 0
Treatment at time of study   
   None 10 0
   ≤10 mg/day prednisolone 28 9
   Immunosuppressive agents 7 1
  1. * Except where indicated otherwise, values are the number of patients.